Get Ready for Hep C Meds Mavyret and Vosevi

You'll see big changes in treating hepatitis C due to the new oral antivirals, Mavyret and Vosevi.

Expect to get more involved in managing hep C...just like you're managing heart disease, diabetes, etc. The newer hep C meds are easier to initiate, require less monitoring, and are better tolerated.

Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote